Comparison of effects of amitriptyline and venlafaxine on cognitive and psychomotor functions in healthy volunteers: A randomized parallel group study

Amitriptyline; Venlafaxine; Psychomotor and Cognitive Function; Critical Flicker Frequency; Choice Reaction Time; Six Letter Cancellation Test; Digit Symbol Substitution Test; Arithmetic Ability Test; Zigzag Test; Leeds Sleep Evaluation Questionnaire INTRODUCTION Depression and anxiety disorders are...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:National journal of physiology, pharmacy and pharmacology pharmacy and pharmacology, 2020, Vol.10 (10), p.1-935
Hauptverfasser: Shah, Rima, Patel, Sumit, Chaudhary, Vipul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Amitriptyline; Venlafaxine; Psychomotor and Cognitive Function; Critical Flicker Frequency; Choice Reaction Time; Six Letter Cancellation Test; Digit Symbol Substitution Test; Arithmetic Ability Test; Zigzag Test; Leeds Sleep Evaluation Questionnaire INTRODUCTION Depression and anxiety disorders are the most common mental illnesses, each affecting in excess of 10-15% of the population at some time in their lives. According to a 2007 report by the Centers for Disease Control and Prevention, antidepressant drugs were the most commonly prescribed medications in the USA at the time of the survey. [6] Amitriptyline, a tricyclic antidepressant, apart from inhibiting reuptake of serotonin (5-HT) and norepinephrine, also antagonize a1 adrenergic, H1 histaminic, and muscarinic cholinergic receptors, and thus compromise the quality of life of the patients by causing psychomotor impairment, somnolence, and tremors etc. [7] Increased understanding of neurotransmitter and receptor interactions led to the development of newer antidepressants with more selective activity such as selective serotonin reuptake inhibitors (SSRIs) and more recently serotonin-norepinephrine reuptake inhibitors (SNRIs).
ISSN:2320-4672
2231-3206
DOI:10.5455/njppp.2020.10.08232202011092020